Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations

2Q Results - Fiscal Year 2017 (Jan-Jun 2017)

Jul 27, 2017 (15:30 JST)

Jul 20: Events & Presentations has been updated with the Time of the Financial Results
Jul 14: Webcast of R&D Conference Call (ISTH 2017)
Jul 11: R&D Conference Call (ISTH 2017)
Jul 04: Events & Presentations has been updated with the date of the Financial Results
Jun 30: Webcast of R&D Conference Call

More

Jul 21

Chugai Files a New Drug Application for Its Bispecific Monoclonal Antibody “Emicizumab” for the Treatment of Congenital Factor VIII Deficiency (Hemophilia A) with Factor VIII Inhibitors

[

PDF 55KB]

Jul 10

Chugai’s Bispecific Antibody “Emicizumab”
Global Phase III Data in Patients with Haemophilia A with Inhibitors
Published in The New England Journal of Medicine Online

[

PDF 108KB]

Jun 29

Appointment of Chugai’s Deputy Chairman Motoo Ueno as
President of Business Ethics Research Center (BERC)

[

PDF 106KB]

Jun 27

Chugai to Sponsor “2017 Wheelchair Softball Tournament in Tokyo”

[

PDF 295KB]

Jun 26

Approval of Additional Dosage for “Actemra® Subcutaneous Injection” Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose

[

PDF 58KB]

More

Management Policy

R&D

Events & Presentations

Events & Presentations

Shareholder Information

TSE Code:4519

Share Graph

Annual Report 2016 (Integrated Edition Including CSR Report)
[ 9.6MB]

Supplementary Materials

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Copyright © Chugai Pharmaceutical Co., Ltd. All rights reserved.